Effects of vaccine in treatment of Hepatitis b patients

Effects of different doses of HBV vaccine on viral load of chronic carrier state of HBV

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202259124N1

Enrollment

120

Registered

2012-08-09

Start date

2007-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B virus carrier. Hepatitis B surface antigen [HBsAg] carrier

Interventions

Intervention 1: Placebo at start, month 1 and month 6. Intervention 2: 1 dose of HBV vaccine at start, month 1 and month 6. Intervention 3: 2 dose of HBV vaccine at start, month 1 and month 6. Interve

Placebo

Treatment - Drugs

Placebo at start, month 1 and month 6

1 dose of HBV vaccine at start, month 1 and month 6

2 dose of HBV vaccine at start, month 1 and month 6

2 doses of HBV vaccine at start, month 1, month 2 and month 6

Eligibility

Sex/Gender

All

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 20 and 65 years; Absence of clinical manifestations of hepatitis B infection; ALT=40; Presence of clinical manifestations of hepatitis B infection

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HBV viral load. Timepoint: Before firt dose of vaccine and 1 month after last dose of vaccine. Method of measurement: Real time PCR of serum samples.	—

Secondary

Measure	Time frame
Levels of ALT. Timepoint: Start of the study; months 2 and 7. Method of measurement: Serologic examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Abdolvahab Moradi

Golestan University of Medical Sciences

abmoradi@yahoo.com+98 17 1442 1651

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026